Synthesis, Characterization, and Cytotoxicity of New Spirooxindoles Engrafted Furan Structural Motif as a Potential Anticancer Agent

A new series of spirooxindoles based on ethylene derivatives having furan aryl moiety are reported. The new hybrids were achieved via [3 + 2] cycloaddition reaction as an economic one-step efficient approach. The final constructed spirooxindoles have four contiguous asymmetric carbon centers. The structure of 3a is exclusively confirmed using X-ray single crystal diffraction. The supramolecular structure of 3a is controlled by O center dot center dot center dot H, H center dot center dot center dot H, and C center dot center dot center dot C intermolecular contacts. It includes layered molecules interconnected weak C-H center dot center dot center dot O (2.675 angstrom), H center dot center dot center dot H (2.269 angstrom), and relatively short Cl center dot center dot center dot Br interhalogen interactions [3.4500(11)angstrom]. Using Hirshfeld analysis, the percentages of these intermolecular contacts are 10.6, 25.7, 6.4, and 6.2%, respectively. The spirooxindoles along with ethylene derivatives having furan aryl moiety were assessed against breast (MCF7) and liver (HepG2) cancer cell lines. The results indicated that the new chalcone 3b showed excellent activity in both cell lines (MCF7 and HepG2) with IC50 = 4.1 +/- 0.10 mu M/mL (MCF7) and 3.5 +/- 0.07 mu M/mL (HepG2) compared to staurosporine with 4.3 and 2.92 folds. Spirooxindoles 6d (IC50 = 4.3 +/- 0.18 mu M/mL), 6f (IC50 = 10.3 +/- 0.40 mu M/mL), 6i (IC50 = 10.7 +/- 0.38 mu M/mL), and 6j (IC50 = 4.7 +/- 0.18 mu M/mL) exhibited potential activity against breast adenocarcinoma, while compounds 6d (IC50 = 6.9 +/- 0.23 mu M/mL) and 6f (IC50 = 3.5 +/- 0.11 mu M/mL) were the most active hybrids against human liver cancer cell line (HepG2) compared to staurosporine [IC50 = 17.8 +/- 0.50 mu M/mL (MCF7) and 10.3 +/- 0.23 mu M/mL (HepG2)]. Molecular docking study exhibited the virtual mechanism of binding of compound 3b as a dual inhibitor of EGFR/CDK-2 proteins, and this may highlight the molecular targets for its cytotoxic activity.